REGENERON PHARMACEUTICALS (REGN) Stock Price, Quote, News and Overview

What is the stock price of REGENERON PHARMACEUTICALS today?

The current stock price of REGN is 599.76 USD. The price increased by 2.03% in the last trading session.

What is the ticker symbol for REGENERON PHARMACEUTICALS stock?

The exchange symbol of REGENERON PHARMACEUTICALS is REGN and it is listed on the Nasdaq exchange.

On which exchange is REGN stock listed?

REGN stock is listed on the Nasdaq exchange.

What is the price forecast or stock price prediction for REGENERON PHARMACEUTICALS stock?

34 analysts have analysed REGN and the average price target is 952.52 USD. This implies a price increase of 58.82% is expected in the next year compared to the current price of 599.76. Check the REGENERON PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.

What is REGENERON PHARMACEUTICALS worth?

REGENERON PHARMACEUTICALS (REGN) has a market capitalization of 65.57B USD. This makes REGN a Large Cap stock.

How many employees does REGENERON PHARMACEUTICALS have?

REGENERON PHARMACEUTICALS (REGN) currently has 13926 employees.

What are the support and resistance levels for REGENERON PHARMACEUTICALS (REGN) stock?

REGENERON PHARMACEUTICALS (REGN) has a support level at 554.17 and a resistance level at 599.77. Check the full technical report for a detailed analysis of REGN support and resistance levels.

Is REGENERON PHARMACEUTICALS (REGN) expected to grow?

The Revenue of REGENERON PHARMACEUTICALS (REGN) is expected to grow by 2.35% in the next year. Check the estimates tab for more information on the REGN EPS, Sales, EBIT and EBITDA future analyst estimates.

Should I buy REGENERON PHARMACEUTICALS (REGN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:

• The Technical Analysis (TA) tab contains a technical analysis of REGN, looking at technical quality and support and resistance levels
• The Fundamental Analysis (FA) tab contains a fundamental analysis of REGN, evaluating the profitability, health, valuation and growth aspects
• REGENERON PHARMACEUTICALS (REGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
• REGENERON PHARMACEUTICALS (REGN) Sales and EPS estimates to see what analysts future expectations are.
• REGENERON PHARMACEUTICALS (REGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
• REGENERON PHARMACEUTICALS (REGN) Insider and Institutional Ownership to learn about the owners and their transactions.
• REGENERON PHARMACEUTICALS (REGN) Stock Chart to make your own analysis
• REGENERON PHARMACEUTICALS (REGN) Latest news and press-releases to stay up to date.

Does REGENERON PHARMACEUTICALS (REGN) stock pay dividends?

REGENERON PHARMACEUTICALS (REGN) has a dividend yield of 0.63%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of REGN dividend history, reliability and sustainability.

When does REGENERON PHARMACEUTICALS (REGN) report earnings?

REGENERON PHARMACEUTICALS (REGN) will report earnings on 2025-04-29, before the market open.

What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (REGN)?

The PE ratio for REGENERON PHARMACEUTICALS (REGN) is 13.14. This is based on the reported non-GAAP earnings per share of 45.64 and the current share price of 599.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for REGN.

What is the Short Interest ratio of REGENERON PHARMACEUTICALS (REGN) stock?

The outstanding short interest for REGENERON PHARMACEUTICALS (REGN) is 2.43% of its float. Check the ownership tab for more information on the REGN short interest.

ChartMill assigns a fundamental rating of 7 / 10 to REGN. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues.

Over the last trailing twelve months REGN reported a non-GAAP Earnings per Share(EPS) of 45.64. The EPS increased by 4.25% compared to the year before.

ChartMill assigns a Buy % Consensus number of 80% to REGN. The Buy consensus is the average rating of analysts ratings from 34 analysts.

For the next year, analysts expect an EPS growth of -7.85% and a revenue growth 2.35% for REGN